Agenda

2025-11-16 17:00 UTC Gail J. Roboz

Welcome and introductions
2025-11-16 17:05 UTC Jorge Sierra

FLT3 mutations in AML: Types, prevalence, and clinical significance
2025-11-16 17:15 UTC Jorge Cortes

Comparing treatment options for patients with FLT3-ITD and
-TKD mutations
2025-11-16 17:35 UTC Gail J. Roboz

Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations
2025-11-16 17:50 UTC Gail J. Roboz

Closing remarks

Learning objectives

After attending this webinar, learners will be able to:

Describe novel therapeutic targets in GvHD and explain the mechanisms of action for new agents.
Recall the latest data for new agents in development for GvHD and describe the rationale for selecting such treatments based on treatment- and patient-related factors.
Explain how quality of life can be impacted in patients with GvHD and how this can be better managed in clinical practice.

JavaScript Required: This registration form requires JavaScript to function. Please enable JavaScript in your browser settings and refresh the page.

Registration form

Registration is free.

First name

Last name

Country

Your role / background

I have read and agree to the terms & conditions, and I consent to receiving emails from Scientific Education Support in relation to this session.

I consent to receiving emails about future educational opportunities from SES's medical education platforms.

Required fields

Agenda

Welcome and introductions

FLT3 mutations in AML: Types, prevalence, and clinical significance

Comparing treatment options for patients with FLT3-ITD and
-TKD mutations

Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations

Closing remarks

Learning objectives

Registration form

Thank you!

Agenda

Welcome and introductions

FLT3 mutations in AML: Types, prevalence, and clinical significance

Comparing treatment options for patients with FLT3-ITD and -TKD mutations

Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations

Closing remarks

Learning objectives

Registration form

Thank you!

Comparing treatment options for patients with FLT3-ITD and
-TKD mutations